1) Delyon J, Maio M and Lebbé C : The ipilimumab lesson in melanoma : Achieving long-term survival. Semin Oncol 42 : 387─401, 2015
2) Burnet FM : The concept of immunological surveillance. Prog Exp Tumor Res 13 : 1─27, 1970
3) Schreiber RD, Old LJ and Smyth MJ : Cancer Immunoediting : integrating immunity's Roles in Cancer Suppression and promotion. Science 331 : 1565─1570, 2011
4) Melief CJ : Tumor eradication by adoptive transfer of cytototic T Lymphocytes. Adv Cancer Res 58 : 143─175, 1992
5) Fridman WH, Pagès F, Sautès-Fridman C, et al : The immune contexture in human tumours : impact on clinical outcome. Nat Rev Cancer 12 : 298─306, 2012
6) Pardoll DM : The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 : 252─264, 2012
7) Rosenberg SA, Yang JC and Restifo NP : Cancer immunotherapy : moving beyond current vaccines. Nat Med 10 : 909─915, 2004
8) Vansteenkiste JF, Cho BC, Vanakesa T, et al : Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17 : 822─835, 2016
9) Maeda Y, Nishikawa H, Sugiyama D, et al : Detection of self-reactive CD8+T cells with an anergic phenotype in healthy individuals. Science 346 : 1536─1540, 2014
10) Okazaki T, Chikuma S, Iwai Y, et al : A rheostat for immune responses : the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14 : 1212─1218, 2013
11) Ishida Y, Agata Y, Shibahara K, et al : Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11 : 3887─3895, 1992
12) Zou W : Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 : 263─274, 2005
13) Zarek PE, Huang C, Lutz ER, et al : A 2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111 : 251─259, 2008
14) Sakaguchi S, Sakaguchi N, Asano M, et al : Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 : 1151─1164, 1995
15) Baecher-Allan C, Brown JA, Freeman GJ, et al : CD4+CD25high Regulatory cells in human peripheral blood. J Immunol 167 : 1245─1253, 2001
16) Vignali DAA, Collison LW and Workman CJ : How regulatory T cells work. Nat Rev Immunol 8 : 523─532, 2008
17) Nishikawa H and Sakaguchi S : Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27 : 1─7, 2014
18) Young MR, Newby M and Wepsic HT : Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 47 : 100─105, 1987
19) Meyer C, Cagnon L, Costa-Nunes CM, et al : Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63 : 247─257, 2014
20) Postow MA, Chesney J, Pavlick AC, et al : Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med 372 : 2006─2017, 2015